{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:42:59Z","timestamp":1793169779890,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine Reports"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.pmedr.2025.102981","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T02:08:05Z","timestamp":1737252485000},"page":"102981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017\u2013April 2024"],"prefix":"10.1016","volume":"50","author":[{"given":"Yamin","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xucheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pmedr.2025.102981_bb0005","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1080\/21645515.2021.1985890","article-title":"Risk of Guillain-Barr\u00e9 syndrome following herpes zoster, United States, 2010-2018","volume":"17","author":"Anderson","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.pmedr.2025.102981_bb0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"(2022) use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices - United States","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.pmedr.2025.102981_bb0015","volume":"14","author":"Chohan","year":"2022","journal-title":"Recurrence of a Rare Subtype of Guillain-Barr\u00e9 Syndrome Following a Second Dose of the Shingles Vaccine Cureus"},{"key":"10.1016\/j.pmedr.2025.102981_bb0020","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pmedr.2025.102981_bb0025","first-page":"988","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis the lancet","volume":"19","author":"Dagnew","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.pmedr.2025.102981_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"Dooling","year":"2018","journal-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines MMWR Morbidity and mortality weekly report"},{"key":"10.1016\/j.pmedr.2025.102981_bb0035","author":"Food and Drug Administration"},{"key":"10.1016\/j.pmedr.2025.102981_bb0040","first-page":"1623","volume":"181","author":"Goud","year":"2021","journal-title":"Risk of Guillain-Barr\u00e9 Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries JAMA internal medicine"},{"key":"10.1016\/j.pmedr.2025.102981_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix) - United States, October 2017-June","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.pmedr.2025.102981_bb0050","first-page":"1005","volume":"331","author":"Jamieson","year":"2024","journal-title":"Misinformation and the Vaccine Adverse Event Reporting System Jama"},{"key":"10.1016\/j.pmedr.2025.102981_bb0055","first-page":"2060668","volume":"18","author":"Janusz","year":"2022","journal-title":"Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults Human vaccines & immunotherapeutics"},{"key":"10.1016\/j.pmedr.2025.102981_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med."},{"key":"10.1016\/j.pmedr.2025.102981_bb0065","volume":"4","author":"Kawai","year":"2014","journal-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective BMJ open"},{"key":"10.1016\/j.pmedr.2025.102981_bb0070","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pmedr.2025.102981_bb0075","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pmedr.2025.102981_bb0080","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials","volume":"37","author":"L\u00f3pez-Fauqued","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.pmedr.2025.102981_bb0085","author":"Medical Dictionary for Regulatory Activities"},{"key":"10.1016\/j.pmedr.2025.102981_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001919","article-title":"Acute cardiovascular events after herpes zoster: a self-controlled case series analysis in vaccinated and unvaccinated older residents of the United States","volume":"12","author":"Minassian","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.pmedr.2025.102981_bb0095","author":"Nelson"},{"key":"10.1016\/j.pmedr.2025.102981_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/aje\/kwac170","article-title":"Active Postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data","volume":"192","author":"Nelson","year":"2023","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.pmedr.2025.102981_bb0105","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1016\/j.vaccine.2020.07.049","article-title":"A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients","volume":"38","author":"Racine","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.pmedr.2025.102981_bb0110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.pmedr.2025.102981_bb0115","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.pmedr.2025.102981_bb0120","series-title":"Safety of the 9-valent human papillomavirus vaccine pediatrics 144","author":"Shimabukuro","year":"2019"},{"key":"10.1016\/j.pmedr.2025.102981_bb0125","first-page":"381","volume":"25","author":"Szarfman","year":"2002","journal-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database Drug safety"},{"key":"10.1016\/j.pmedr.2025.102981_bb0130","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Tavares-Da-Silva","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.pmedr.2025.102981_bb0135","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1016\/j.vaccine.2020.03.054","article-title":"Safety of live attenuated herpes zoster vaccine in adults 70-79 years: a self-controlled case series analysis using primary care data from Australia\u2019s MedicineInsight program","volume":"38","author":"Totterdell","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.pmedr.2025.102981_bb0140","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.ophtha.2016.03.005","article-title":"Epidemiology of herpes zoster Ophthalmicus: recurrence and chronicity","volume":"123","author":"Tran","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pmedr.2025.102981_bb0145","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2796.2011.02474.x","article-title":"Safety of zoster vaccine in adults from a large managed-care cohort: a vaccine safety datalink study","volume":"271","author":"Tseng","year":"2012","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.pmedr.2025.102981_bb0150","author":"US Food and Drug Administration"},{"key":"10.1016\/j.pmedr.2025.102981_bb0155","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: a 10\u00a0year review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.pmedr.2025.102981_bb0160","first-page":"1341","volume":"82","author":"Yawn","year":"2007","journal-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction Mayo Clinic proceedings"},{"key":"10.1016\/j.pmedr.2025.102981_bb0165","first-page":"562","volume":"88","author":"Yawn","year":"2013","journal-title":"Herpes zoster eye complications: rates and trends Mayo Clinic proceedings"}],"container-title":["Preventive Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211335525000208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211335525000208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T10:04:18Z","timestamp":1740650658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211335525000208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"alternative-id":["S2211335525000208"],"URL":"https:\/\/doi.org\/10.1016\/j.pmedr.2025.102981","relation":{},"ISSN":["2211-3355"],"issn-type":[{"value":"2211-3355","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017\u2013April 2024","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmedr.2025.102981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102981"}}